Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
Date:7/10/2014

compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company utilized the services of paid stock promoters to inflate its share price; (ii) contrary to the Company's representations, preparations were not underway for a Phase 3 study for PV-10; and (iii) the Company improperly referred to PV-10 as obtaining a Breakthrough Therapy Designation ("BTD"), and otherwise implied that obtaining that status was inevitable.

On January 23, 2014, an article was published on TheStreet.com, accusing Provectus of artificially inflating the price of its stock by making false representations related to the commencement of Phase III clinical trials. 

On this news, the Company's shares declined $3.35, or over 64%, to close at $21.87 on January 23, 2014.

Prior to May 20, 2014, the Company's website improperly described its PV-10 drug as a "breakthrough" drug for skin cancer, prior to the FDA's designation of the drug as such.  On May 20, 2014, the Company updated its website and changed the description of PV-10 to "An Investigational Drug for Cancer" and included language clearly indicating that the drug was still awaiting BTD designation by the FDA.

On this news, Provectus securities declined $0.31 per share, or over 10%, to close at $2.70 per share on May 20, 2014.

On May 21, 2014, an article was published on SeekingAlpha.com alleging that the Company was tied to stock promoters that improperly marketed the Company's stock to unsophisticated retail investors, thus artificially inflating the price of the Company's shares.  The article noted that trading in many of the other companies associated with these stock promoters was recently halted by the SEC.  That same day, Provectus issued a press release refuting the allegations of the SeekingAlpha.com article.  Provectus specifically noted that PV-10, its investigational metasta
'/>"/>

SOURCE Pomerantz LLP
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders Best Interests
2. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
3. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
4. Red alert: Body kills spontaneous blood cancers on a daily basis
5. Media alert: Society of Interventional Radiologys Annual Scientific Meeting
6. Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients
7. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
8. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
9. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
10. Institute of Physics announces 2014 award winners
11. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... low levels of an asbestos-like mineral from Montana more ... for lung disease today, according to research from the ... a mineral with a flaky, fluffy-looking structure. Previous studies ... contained increased levels of an asbestos-like mineral fiber that ...
... is full of examples of creatures that try to look ... potential predators. But to avoid being eaten alive the larvae ... a way exchanging a dollar for a couple of dimes. ... dollar larvae created clones of themselves within 24 hours of ...
... Genome Sequencing Center (GSC) at Washington University in St. Louis, ... the corn genome. In the fall of 2005 ... (USDA) and the Department of Energy (DOE), awarded $32 million ... of the project led by the Washington University GSC is ...
Cached Biology News:Low exposure to asbestos-like mineral from Montana vermiculite may up lung disease risk 2Sand dollar larvae use cloning to 'make change,' confound predators 2Sand dollar larvae use cloning to 'make change,' confound predators 3All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)... 2015  Epic Sciences announced today that President and ... the 35th Annual Cowen and Company Health Care Conference ... Room, 3rd Floor. The conference will be held at ... Epic is developing diagnostic tests of high clinical ... changes that occur during the course of cancer treatments. ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... Schering-Plough Corporation (NYSE: SGP ) will provide ... P. Koestler, Ph.D., executive vice president and president, Schering-Plough ... Conference in San Francisco on Monday, Jan. 12, at ... is expected to talk about the company,s R&D pipeline ...
... LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., ... that GSK has resubmitted the New Drug Application (NDA) ... approval of Solzira (TM) (gabapentin enacarbil) Extended ... Restless Legs Syndrome (RLS). The FDA had requested ...
... LONDON, January 9 UK medical technology company,BioCeramic ... Stephan Rietiker,has joined the company,s Board of Directors. ... in BioCeramic Therapeutics, targeted sectors,particularly as former President ... follows the recent appointment of another renowned,figure, Sir ...
Cached Biology Technology:GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3Dr Stephan Rietiker Joins BioCeramic Therapeutics 2
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
... Cloning Kit enables you to prepare, in ... primary cosmid library of genomic DNA for ... High efficiency cosmid library construction is accomplished ... First, genomic DNA is randomly sheared by ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: